These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 11022716)
1. [Basic and clinical characteristics of flutamide]. Suzuki K; Nakazato H; Kurokawa K; Yamanaka H Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716 [No Abstract] [Full Text] [Related]
2. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. Pitts WR BJU Int; 2004 May; 93(7):1119-20. PubMed ID: 15142186 [No Abstract] [Full Text] [Related]
3. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963 [TBL] [Abstract][Full Text] [Related]
4. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist. Boudreaux KJ; Chang SS BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172 [No Abstract] [Full Text] [Related]
5. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer. Eastham JA; Sartor O J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206 [No Abstract] [Full Text] [Related]
6. Chemotherapy and prostate cancer. Dacker R Radiol Technol; 1997; 68(3):194-5. PubMed ID: 9008013 [No Abstract] [Full Text] [Related]
9. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782 [No Abstract] [Full Text] [Related]
10. Hormone-refractory prostate cancer: what have we learned? Wirth MP BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362 [No Abstract] [Full Text] [Related]
11. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy. Scalliet P Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815 [No Abstract] [Full Text] [Related]
16. [Expression of androgen receptor protein in hormone refractory prostate cancer]. Zhang Y; Chen W; Hu XK; Gui ZN Ai Zheng; 2003 Jan; 22(1):95-7. PubMed ID: 12561446 [TBL] [Abstract][Full Text] [Related]
17. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Blackledge G; Kolvenbag G; Nash A Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. Miyake H; Hara I; Eto H BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202 [TBL] [Abstract][Full Text] [Related]
19. [Cancer of the prostate: new hormone therapies]. Namer M; Boublil JL; Kather R; Cavaglione G Bull Cancer; 1986; 73(1):47-55. PubMed ID: 3779122 [TBL] [Abstract][Full Text] [Related]
20. Hormonal treatment for progression. Miller K Eur J Cancer; 2009 Sep; 45 Suppl 1():158-60. PubMed ID: 19775614 [No Abstract] [Full Text] [Related] [Next] [New Search]